Recurrent DVT (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in recurrent DVT (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Fatal PE (3 to 12 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in fatal PE (3 to 12 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent PE · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in recurrent PEa compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Major bleedinge · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in major bleedinge compared with conventional anticoagulation (low certainty).
1 finding from 1 review
Health‐related quality of life · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent VTEc · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in recurrent VTEc compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
DVTd · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in DVTd compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleedinge · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral direct thrombin inhibitors (DTIs) showed no clear difference in major bleedinge compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Health‐related quality of life · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent PE · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in recurrent PEa compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Recurrent VTEc · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in recurrent VTEc compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
DVTd · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in DVTd compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
Total mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in total mortality compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin showed no clear difference in cardiovascular mortality compared with placebo (low certainty).
1 finding from 1 review
Non‐fatal cardiovascular events · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin may leads to lower non‐fatal cardiovascular events compared with placebo (low certainty).
1 finding from 1 review
Major bleedinga · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin leads to higher major bleedinga compared with placebo (high certainty).
1 finding from 1 review
Cardiovascular events · adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were…
Aspirin may leads to lower all cardiovascular events compared with placebo (low certainty).
1 finding from 1 review
Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) showed no clear difference in any thromboembolic event compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review